493
Participants
Start Date
September 30, 2011
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2013
Aripiprazole (Abilify®) IM Depot Injection
"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
New York
Wards Island
New York
New York
Brooklyn
Brooklyn
Brooklyn
Syracuse
Buffalo
Amherst
Rochester
Rochester
McMurray
Scranton
Sellersville
Phoenixville
Durham
Charlotte
Decatur
Marietta
Atlanta
Saint Augustine
Jacksonville Beach
Orange City
Orlando
Hialeah
Miami
Miami
Coral Gables
Miami
Miami
South Miami
Miami
Miami
Doral
Plantation
Oakland Park
Boynton Beach
Tampa
Tampa
St. Petersburg
Dothan
Franklin
Memphis
Garfield Heights
Canton
Mason
South Bend
Bloomfield Hills
Paw Paw
Grand Rapids
Milwaukee
Minneapolis
Sioux Falls
Joliet
Naperville
Norwalk
St Louis
Creve Coeur
Saint Charles
Kansas City
Kansas City
Topeka
Witchita
Lincoln
North Platte
Little Rock
Fayetteville
Oklahoma City
Dallas
Houston
Houston
Wharton
San Antonio
Austin
Centennial
Salt Lake City
Tucson
Albuquerque
Sparks
Downey
Torrance
Bellflower
Carson
Glendale
Glendale
National City
Escondido
Oceanside
San Diego
San Diego
San Diego
Riverside
Costa Mesa
Paramount
Santa Ana
Anaheim
Anaheim
Garden Grove
San Francisco
Palo Alto
Oakland
Bellevue
Bothell
Kirkland
Spokane
Los Angeles
Orange
Oklahoma City
Pasadena
Middletown
New Brittain
Norwalk
Chicago
Boston
Brockton
Newton
Nashua
Dallas
Penticton
Halifax
Brampton
Chatham
Montreal
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY